<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005575'>Hemolytic uremic syndrome</z:hpo> (HUS) is related to a renal <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e>, inducing <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> (ARF) </plain></SENT>
<SENT sid="1" pm="."><plain>Its pathogenesis involves an activation/lesion of microvascular endothelial cells, mainly in the renal vasculature, secondary to <z:mp ids='MP_0001794'>bacterial</z:mp> toxins, drugs, or autoantibodies </plain></SENT>
<SENT sid="2" pm="."><plain>An overactivation of the complement alternate pathway secondary to a heterozygote deficiency of regulatory proteins (factor H, factor I or <z:chebi fb="17" ids="50099">MCP</z:chebi>) or to an activating mutation of factor B or C3 can also result in HUS </plain></SENT>
<SENT sid="3" pm="."><plain>Less frequently, renal microthrombi are due to an acquired or a constitutional deficiency in ADAMTS-13, the protease cleaving von Wilebrand factor </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001878'>Hemolytic anemia</z:hpo> with <z:hpo ids='HP_0001981'>schistocytes</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> without evidence of <z:hpo ids='HP_0005521'>disseminated intravascular coagulation</z:hpo>, and <z:hpo ids='HP_0000083'>renal failure</z:hpo> are consistently found </plain></SENT>
<SENT sid="5" pm="."><plain>In typical HUS, a prodromal <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, with blood in the stools, is observed, related to pathogenic enterobacteria, most frequently E </plain></SENT>
<SENT sid="6" pm="."><plain>Coli O157:H7 </plain></SENT>
<SENT sid="7" pm="."><plain>HUS may also occur in the post partum period, and is then related to a factor H or <z:e sem="disease" ids="C0001733" disease_type="Disease or Syndrome" abbrv="">factor I deficiency</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>HUS may also occur after various treatments such as <z:chebi fb="0" ids="27504">mitomycin C</z:chebi>, <z:chebi fb="0" ids="175901">gemcitabine</z:chebi>, <z:chebi fb="0" ids="4031">ciclosporin</z:chebi> A, or tacrolimus, and as reported more recently bevacizumab, an anti VEGF antibody </plain></SENT>
<SENT sid="9" pm="."><plain>Atypical HUS are not associated with <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, may be <z:hpo ids='HP_0003745'>sporadic</z:hpo> or familial, and can be related to an overactivation of the complement alternate pathway </plain></SENT>
<SENT sid="10" pm="."><plain>More recently, some of them have been related to a mutation of thrombomodulin, which also regulates the alternate pathway of complement </plain></SENT>
<SENT sid="11" pm="."><plain>In adults, several HUS are encountered in the course of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000112'>nephropathies</z:hpo>: <z:e sem="disease" ids="C0948347" disease_type="Disease or Syndrome" abbrv="">nephroangiosclerosis</z:e>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo>, post irradiation <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, <z:hpo ids='HP_0100324'>scleroderma</z:hpo>, <z:e sem="disease" ids="C0024141" disease_type="Disease or Syndrome" abbrv="">disseminated lupus erythematosus</z:e>, <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Overall the prognosis of HUS has improved, with a patient survival greater than 85% at 1 year </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0003774'>Chronic renal failure</z:hpo> is observed as a sequella in 20 to 65% of the cases </plain></SENT>
<SENT sid="14" pm="."><plain>Plasma infusions and plasma exchanges are effective in most of the cases to treat <z:mp ids='MP_0010163'>hemolysis</z:mp> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>Steroid therapy is debated, as well as immunosuppressive drugs, including rituximab, in autoimmune forms </plain></SENT>
<SENT sid="16" pm="."><plain>A new monoclonal anti-C5 antibody is tested, and seems to be effective in atypical HUS with abnormal complement alternate pathway activation </plain></SENT>
<SENT sid="17" pm="."><plain>If terminal <z:hpo ids='HP_0000083'>renal failure</z:hpo> occurs, renal transplantation can be performed but the risk of recurrence, which very low in post infectious forms of HUS, is about 70 to 80% in genetic forms of complement regulatory <z:e sem="disease" ids="C0033626" disease_type="Disease or Syndrome" abbrv="">protein deficiency</z:e> </plain></SENT>
</text></document>